Please assess the completion status of the following clinical trial:

Trial Title: The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Peripheral arterial disease~* Planned angioplasty or stenting of superficial femoral artery or popliteal artery.~Exclusion Criteria:~* Patients treated on an emergency basis~* Planned intervention on prior site of open surgical intervention (autogenous or autologous bypass, endarterectomy, or patch angioplasty)~* Planned intervention at site exclusive of superficial femoral artery or popliteal artery~* Planned re-stenting at site of prior stent placement~* Planned re-angioplasty at site of prior angioplasty~* Known inability to tolerate antiplatelet regimen before enrollment~* Patients who plan on receiving follow up care outside the University of Pittsburgh Medical Center~* Current use of prasugrel or ticlopidine~* Current use of oral anticoagulation medication~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Experimental: screening/treating for HPR (Type: EXPERIMENTAL): Participants randomized to this arm will be screened and treated for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.
- Control: guideline based therapy (Type: NO_INTERVENTION): Participants randomized to this arm will receive usual care without screening for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.

Based on this trial design, predict the completion outcome and termination type (if applicable).